A perspective on antiviral resistance

被引：26

作者：

Griffiths, Paul D. ^{[1
]}

机构：

[1] UCL Med Sch, Ctr Virol, London NW3 2PF, England

来源：

JOURNAL OF CLINICAL VIROLOGY | 2009年 / 46卷 / 01期

关键词：

HSV; CMV; HIV; HBV; Antivirals; Resistance; HERPES-SIMPLEX-VIRUS; INTEGRASE INHIBITOR RALTEGRAVIR; ACYCLOVIR-RESISTANT; THYMIDINE KINASE; CONTROLLED-TRIAL; CYTOMEGALOVIRUS DISEASE; ANTIRETROVIRAL THERAPY; ADEFOVIR DIPIVOXIL; GENITAL HERPES; HEPATITIS-B;

D O I：

10.1016/j.jcv.2009.06.017

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

More than 25 years after the licensure of aciclovir and then penciclovir, followed by their respective prodrugs valaciclovir and famciclovir, cases of clinically relevant resistance to these drugs in immunocompetent individuals remain very rare. The aim of this review is to focus on the mechanism of action of these anti HSV drugs and then briefly compare this favourable outcome with that of CMV, HIV, HBV and influenza. A central theme is that resistance is an epiphenomenon of failure to suppress virus replication, so that improved potency and selectivity should be prioritised when developing new drugs rather than activity against resistant strains per se. (C) 2009 Elsevier B.V. All rights reserved.

引用

收藏

页码：3 / 8

页数：6

相关论文

共 75 条

[1] Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy [J].

Bacon, TH ;

Levin, MJ ;

Leary, JJ ;

Sarisky, RT ;

Sutton, D .

CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (01) :114-+

[2] Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis [J].

Bacon, TH ;

Boon, RJ ;

Schultz, M ;

Hodges-Savola, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) :3042-3044

[3] A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS [J].

BALFOUR, HH ;

CHACE, BA ;

STAPLETON, JT ;

SIMMONS, RL ;

FRYD, DS .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) :1381-1387

[4]

Biswas Subhajit, 2008, Antiviral Chemistry & Chemotherapy, V19, P1

[5] Predicting and preventing the emergence of antiviral drug resistance in HSV-2 [J].

Blower, SM ;

Porco, TC ;

Darby, G .

NATURE MEDICINE, 1998, 4 (06) :673-678

[6] Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: a UK-based survey [J].

Boon, RJ ;

Bacon, TH ;

Robey, HL ;

Coleman, TJ ;

Connolly, A ;

Crosson, P ;

Sacks, SL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (02) :324-325

[7] Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012) [J].

Boyd, Mark A. ;

Dixit, Narendra M. ;

Siangphoe, Umaporn ;

Buss, Neil E. ;

Salgo, Miklos P. ;

Lange, Joep M. A. ;

Phanuphak, Praphan ;

Cooper, David A. ;

Perelson, Alan S. ;

Ruxrungtham, Kiat .

JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (09) :1319-1322

[8]

Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725

[9] Efficacy and tolerability of initial antiretroviral therapy: a systematic review [J].

Carr, Andrew ;

Amin, Janaki .

AIDS, 2009, 23 (03) :343-353

[10] Resistant herpes simplex virus type 1 infection:: An emerging concern after allogeneic stem cell transplantation [J].

Chen, Y ;

Scieux, C ;

Garrait, V ;

Socié, G ;

Rocha, V ;

Molina, JM ;

Thouvenot, D ;

Morfin, F ;

Hocqueloux, L ;

Garderet, L ;

Espérou, H ;

Sélimi, F ;

Devergie, A ;

Leleu, G ;

Aymard, M ;

Morinet, F ;

Gluckman, E ;

Ribaud, P .

CLINICAL INFECTIOUS DISEASES, 2000, 31 (04) :927-935

← 1 2 3 4 5 6 7 8 →